Atypical Hemolytic Uremic Syndrome
Hematology·MeSH: Atypical Hemolytic Uremic Syndrome
Prevalence
0.1 / 100K
7 drugs in development·5 companies·8 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Ultomiris | Xencor Inc (XNCR) |
Phase 3(2)
Phase 2(3)
Phase 4(1)
| Drug | Company |
|---|---|
| Ravulizumab | ASTRAZENECA PLC (AZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Atypical Hemolytic Uremic Syndrome?
BioSniper tracks 7 drugs in development for Atypical Hemolytic Uremic Syndrome across 5 companies.
How many clinical trials target Atypical Hemolytic Uremic Syndrome?
There are 8 clinical trials targeting Atypical Hemolytic Uremic Syndrome tracked by BioSniper.
What is the prevalence of Atypical Hemolytic Uremic Syndrome?
The estimated prevalence of Atypical Hemolytic Uremic Syndrome is approximately 0.1 per 100,000 population.
Deep-dive into Atypical Hemolytic Uremic Syndrome
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis